Literature DB >> 20830664

HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder.

P Bech1, P Boyer, J-M Germain, K Padmanabhan, V Haudiquet, B Pitrosky, K A Tourian.   

Abstract

INTRODUCTION: This retrospective analysis compared sensitivity to change on the 17-item and 6-item Hamilton Rating Scales For Depression (HAM-D (17) and HAM-D (6), respectively) in relation to antidepressant dose and baseline depression severity.
METHODS: Data were derived from 6 randomized, double-blind, placebo-controlled, 8-week trials of fixed-dose desvenlafaxine (50, 100, 200 or 400 mg/d) for major depressive disorder. HAM-D (17) and HAM-D (6) effect sizes were assessed.
RESULTS: HAM-D (17) effect sizes were negative (favoured placebo) for higher desvenlafaxine doses (200-400 mg/d) at week 1, but were positive for all doses after week 2, with no clear dose-response pattern. However, HAM-D (6) effect sizes were positive for all doses at all weeks. Effect sizes were consistently greater for HAM-D (6) vs. HAM-D (17), regardless of time spent under therapy. Effect sizes were greater for HAM-D (6) vs. HAM-D (17) for all desvenlafaxine doses among patients with baseline HAM-D (17) <25, but not among patients with baseline HAM-D (17) ≥ 25. DISCUSSION: The HAM-D (6) demonstrated greater sensitivity to change and robustness than the HAM-D (17), supporting the greater homogeneity of the HAM-D (6). © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20830664     DOI: 10.1055/s-0030-1263173

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  10 in total

1.  Sensitivity to changes during antidepressant treatment: a comparison of unidimensional subscales of the Inventory of Depressive Symptomatology (IDS-C) and the Hamilton Depression Rating Scale (HAMD) in patients with mild major, minor or subsyndromal depression.

Authors:  Isabella Helmreich; Stefanie Wagner; Roland Mergl; Antje-Kathrin Allgaier; Martin Hautzinger; Verena Henkel; Ulrich Hegerl; André Tadić
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-09-30       Impact factor: 5.270

2.  The responsiveness of the different versions of the Hamilton Depression Scale.

Authors:  Per Bech
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

3.  Toward a very brief self-report to assess the core symptoms of depression (VQIDS-SR5 ).

Authors:  N De La Garza; A John Rush; B D Grannemann; M H Trivedi
Journal:  Acta Psychiatr Scand       Date:  2017-03-17       Impact factor: 6.392

4.  The severity of psychiatric disorders.

Authors:  Mark Zimmerman; Theresa A Morgan; Kasey Stanton
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

5.  Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial.

Authors:  Patrice Boyer; Cécile Vialet; Eunhee Hwang; Karen A Tourian
Journal:  Prim Care Companion CNS Disord       Date:  2015-08-27

6.  Measuring psychotic depression.

Authors:  S D Østergaard; B S Meyers; A J Flint; B H Mulsant; E M Whyte; C M Ulbricht; P Bech; A J Rothschild
Journal:  Acta Psychiatr Scand       Date:  2013-06-25       Impact factor: 6.392

7.  Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales.

Authors:  David A Luckenbaugh; Rezvan Ameli; Nancy E Brutsche; Carlos A Zarate
Journal:  J Psychiatr Res       Date:  2014-12-27       Impact factor: 4.791

8.  Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.

Authors:  Marlene P Freeman; George I Papakostas; Bettina Hoeppner; Erica Mazzone; Heidi Judge; Cristina Cusin; Sanjay Mathew; Gerard Sanacora; Dan Iosifescu; Charles DeBattista; Madhukar H Trivedi; Maurizio Fava
Journal:  J Psychiatr Res       Date:  2019-01-08       Impact factor: 4.791

9.  Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder.

Authors:  Marlene P Freeman; Rebecca S Hock; George I Papakostas; Heidi Judge; Cristina Cusin; Sanjay J Mathew; Gerard Sanacora; Dan V Iosifescu; Charles DeBattista; Madhukar H Trivedi; Maurizio Fava
Journal:  J Clin Psychopharmacol       Date:  2020 May/Jun       Impact factor: 3.118

10.  Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.

Authors:  Allison C Nugent; Elizabeth D Ballard; Todd D Gould; Lawrence T Park; Ruin Moaddel; Nancy E Brutsche; Carlos A Zarate
Journal:  Mol Psychiatry       Date:  2018-02-27       Impact factor: 15.992

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.